Stephen Welch

Stephen Andrew Welch is currently President & Chief Executive Officer at Par Health, Inc. Current roles also include Director positions at Mallinckrodt Chemical Ltd., Mallinckrodt Chemical Holdings (U.K.) Ltd., Mallinckrodt Medical Holdings (UK) Ltd., Mallinckrodt ARD Holdings Ltd., Mallinckrodt Enterprises UK Ltd., MUSHI UK Holdings Ltd., Mallinckrodt Equinox Ltd., and Mallinckrodt UK Ltd. Since 2022, the role of Executive Vice President & Head-Specialty Generics at Keenova Therapeutics Plc is held.
Former roles include Director at MKG Medical UK Ltd., Head-Tax Department at Human Genome Sciences, Inc., Member of the California State Bar Association, Head-Tax Department at PharMerica Corp., and Chief Transformation Officer at Mallinckrodt Pharmaceuticals Ltd. Education includes undergraduate studies at California State University-Bakersfield and graduate studies at Georgetown University Law Center.